IFM Investors Pty Ltd lifted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 14.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,994 shares of the biopharmaceutical company’s stock after acquiring an additional 2,042 shares during the quarter. IFM Investors Pty Ltd’s holdings in Alexion Pharmaceuticals were worth $2,095,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALXN. FMR LLC boosted its holdings in shares of Alexion Pharmaceuticals by 25.1% during the 4th quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock valued at $2,570,135,000 after acquiring an additional 5,301,272 shares in the last quarter. Norges Bank acquired a new stake in shares of Alexion Pharmaceuticals during the 4th quarter valued at $388,934,000. Artisan Partners Limited Partnership boosted its holdings in shares of Alexion Pharmaceuticals by 220.9% during the 1st quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock valued at $574,278,000 after acquiring an additional 2,924,550 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Alexion Pharmaceuticals by 17.3% during the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock valued at $1,384,440,000 after acquiring an additional 1,512,545 shares in the last quarter. Finally, FIL Ltd boosted its holdings in shares of Alexion Pharmaceuticals by 629.3% during the 1st quarter. FIL Ltd now owns 1,208,567 shares of the biopharmaceutical company’s stock valued at $163,373,000 after acquiring an additional 1,042,846 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

In other news, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the transaction, the executive vice president now directly owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Aradhana Sarin sold 578 shares of Alexion Pharmaceuticals stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $132.00, for a total value of $76,296.00. Following the completion of the transaction, the insider now directly owns 30,201 shares of the company’s stock, valued at $3,986,532. The disclosure for this sale can be found here. Over the last three months, insiders sold 428,567 shares of company stock valued at $53,420,869. Corporate insiders own 4.08% of the company’s stock.

ALXN stock opened at $114.63 on Friday. The stock has a 50-day simple moving average of $124.13. Alexion Pharmaceuticals, Inc. has a 1-year low of $92.56 and a 1-year high of $141.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.36 and a current ratio of 4.04. The company has a market cap of $26.47 billion, a price-to-earnings ratio of 16.17, a PEG ratio of 1.10 and a beta of 1.64.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.51. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period last year, the company posted $2.07 EPS. The business’s quarterly revenue was up 15.1% on a year-over-year basis. On average, equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.68 earnings per share for the current year.

Several research analysts recently issued reports on the company. Zacks Investment Research lowered Hammerson from a “hold” rating to a “sell” rating in a research report on Friday, May 24th. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Goldman Sachs Group raised Lenovo Group from a “neutral” rating to a “buy” rating in a research report on Thursday, May 23rd. They noted that the move was a valuation call. Wedbush set a $190.00 target price on Home Depot and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. Finally, Raymond James raised their target price on Spotify Technology from $172.00 to $180.00 and gave the stock a “strong-buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $161.47.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Forex

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.